Pediatric Annals

Editorial Free

The Antibiotic Crisis

Stanford T. Shulman, MD

Much has been written in the last few years about the worldwide antibiotic crisis, which, simply stated, is that although antibiotic resistance among bacteria continues to increase, the pipeline for new, systemically administered antibiotics continues to be dry. The Infectious Diseases Society of America (IDSA) and other organizations have been sounding the alarm for several years; finally, it looks as though it is starting to be heard.

The IDSA program is called the “10 × ’20 Initiative,” with the goal to develop 10 new, safe, and effective antibiotics by 2020. In a nutshell, substantial financial incentives from government and other agencies are necessary to encourage antibiotic research. As it is now, development of antibiotics is nearly nil because pharmaceutical companies recognize that they can reap greater profit from a new statin drug, antihypertensive drug, hypoglycemic drug, or agent to treat erectile dysfunction than from launching a new antibiotic.

Historical Perspective

For me, the historical impact of antibiotics upon childhood infections has been re-emphasized by two recent experiences that recall the earliest antibiotic days of the late 1930s. The first experience was when I received a letter written by an 82-year-old woman who said she was treated at Children’s Memorial Hospital in Chicago in 1939 for pneumococcal meningitis, and she was seeking information about her treatment.

Astonishingly, our medical records department still had her records! They revealed that she had been treated at age 8 years for severe pneumococcal type XIX meningitis (comatose, rigid neck, 11,000 white blood cells in the cerebrospinal fluid) with three doses of rabbit-type XIX pneumococcal antisera and 16 days of sulfanilamide/sulfapyridine. The treatment had a spectacular outcome: she graduated Phi Beta Kappa from Northwestern University about 12 years later and is still healthy, active, emailing, driving, and teaching college prep courses. An outcome like that from pneumococcal meningitis was unprecedented prior to the availability of the sulfa agents in the 1 to 2 years preceding 1939.

The second experience relates to research I am doing for a history I am writing of Children’s Memorial Hospital to date. That is a span from 1882 to 2012, when the original facility closed and the state-of-the-art Ann & Robert H. Lurie Children’s Hospital of Chicago opened on June 9, 2012.

Joseph P. Brennemann, MD, hospital Chief of Staff from 1921 to 1940, referred to the development of sulfa agents in the hospital’s Annual Report for 1939, stating that: “In the many years of my medical experience there has been no comparable event … it has come with such suddenness and such startling effect that it seems unbelievable.” He was referring to the impact on children with streptococcal, pneumococcal, gonococcal, or Haemophilus infections.

Dr. Brennemann had graduated from Northwestern University Medical School in 1900 and was one of the most famous pediatricians of his era; he was not easily impressed, but the beginning of the antibiotic era clearly made a strong impression as mortality rates for bacterial meningitis, pneumonia, and many other infections tumbled precipitously. To the practitioner of the era, antibiotics were miraculous, and much of the success of the remarkable sulfa drugs was surpassed within just 5 or 6 years by the impact of penicillin. This truly was remarkable.

Duty to Protect

As a society, we must do what we can to protect the gains of the past 75 years and regain our capability to develop and produce new and better antimicrobial agents.

This Month’s Stamps

I have selected one of my very favorite stamps for this month: a 1978 souvenir sheet from Mauritius that celebrates the 50th anniversary of Sir Alexander Fleming’s discovery of penicillin. This sheet shows a World War I soldier being carried off with a deadly infection at the top left; Fleming’s culture plate with the Penicillium mold inhibiting Staphylococcus aureus at the top right; the microscopic appearance of Penicillium at the lower left; and a child receiving a penicillin shot with the background showing the colonial appearance of Penicillium at the lower right.

 A 1978 souvenir sheet from Mauritius that celebrates the 50th anniversary of Sir Alexander Fleming’s discovery of penicillin.Image courtesy of Stanford T Shulman, MD. 

A 1978 souvenir sheet from Mauritius that celebrates the 50th anniversary of Sir Alexander Fleming’s discovery of penicillin. Image courtesy of Stanford T Shulman, MD.




Pediatric Annals Editor-in-Chief Stanford T. Shulman, MD, is the Virginia H. Rogers Professor of Pediatric Infectious Diseases at Northwestern University Feinberg School of Medicine; and Chief of the Division of Infectious Disease at the Ann and Robert H. Lurie Children’s Hospital, Chicago, IL. Dr. Shulman is the recipient of the AAP 2011 Award for Lifetime Contribution to Infectious Disease Education.

An avid stamp collector, Dr. Shulman chooses relevant stamps from his personal collection to accompany his column each month.

Reach Dr. Shulman via email:


Sign up to receive

Journal E-contents